Sanofi (SNY)
(Delayed Data from NSDQ)
$49.13 USD
-0.23 (-0.47%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $49.13 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SNY 49.13 -0.23(-0.47%)
Will SNY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNY
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
SNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Other News for SNY
Kepler Capital Keeps Their Hold Rating on Sanofi (SNYNF)
Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
GLOBAL BROKER RATINGS: Stifel cuts Caterpillar; HSBC likes Ashtead
Bristol, Sanofi, Takeda gain positive CHMP recommendations
Sanofi Non-GAAP EPS of €1.78, revenue of €10.46B; reaffirms FY24 business EPS guidance